Valtrix Holdings
← Back to portfolio

Cindervale Laboratories

Monitoring — no action needed

Laboratory Services · Research Triangle Park, NC

May 28 – Aug 13, 2026

last 12 weeks of telemetry

Expansion Monitor36 points clear of the escalation threshold with nothing open

Cindervale Laboratories is 36 points below its escalation threshold — resource & capacity is the strongest theme at 36 against a threshold of 72. Nothing is currently escalated, though 2 themes are still climbing. No board direction is outstanding.

36

Highest signal

of 72 threshold

0

Open escalations

nothing open

84%

Participation

coverage sufficient

0

Board actions

none assigned

What needs attention

2 active themes

Resource & Capacity

11 independent participants · 4 functions

Weak Signal36 / 72Rising 5wView evidence →

Reported by 11 independent participants across 4 functions, persistent for 5 weeks and rising.

Execution Bandwidth

9 independent participants · 5 functions

Weak Signal28 / 72Rising 4wView evidence →

Reported by 9 independent participants across 5 functions, persistent for 4 weeks and rising.

Organizational radar

all 8 themes scored

0

Escalated

0

Developing

8

Quiet

View all eight themes

Organizational radar

Cindervale Laboratories across the eight themes

Every company is scored on the same eight themes, shaded against this program's own escalation threshold — so a quiet row means quiet, not unmeasured.

Company
Direction
Bandwidth
Comms
Alignment
Capacity
Talent
Friction
External
6
28
14
7
36
11
11
11

Confidence = unique reporters of a theme ÷ active participants over the rolling 4-week window. A cell turns red once it crosses its company's escalation threshold.

Board response

No board direction outstanding, and nothing open that needs one.

high growth · held since May 2023 · Research Triangle Park, NC

Company context
Employees
290
Signal seats
37
13% enrolled
Revenue
$94M
EBITDA margin
20–23%

Investment thesis

Analytical testing for pharmaceutical and food customers, where outsourcing penetration is still rising.

Known exposures

  • ·Instrument capex needed ahead of contracted volume
  • ·Scientist recruitment competes directly with local pharma

Signal data is PE-exclusive. Portfolio company leadership has no visibility into submissions, themes, or confidence scores.

Beacon detects. Bearing interprets. You decide.